International Journal of Hematology

, 79:37

Antiproliferative Efficacy of the Third-Generation Bisphosphonate, Zoledronic Acid, Combined with Other Anticancer Drugs in Leukemic Cell Lines

Authors

    • Department of Transfusion Medicine and Cell TherapyKyoto University Hospital
  • Junya Kuroda
    • Department of Transfusion Medicine and Cell TherapyKyoto University Hospital
    • Department of Internal MedicineKyoto Prefectural University of Medicine
  • Hidekazu Segawa
    • Department of Transfusion Medicine and Cell TherapyKyoto University Hospital
    • Department of Gastroenterology and HematologyShiga University of Medical Science
  • Kiyoshi Sato
    • Department of Transfusion Medicine and Cell TherapyKyoto University Hospital
    • Department of Thoracic SurgeryFaculty of Medicine, Kyoto University
  • Masaki Nogawa
    • Department of Transfusion Medicine and Cell TherapyKyoto University Hospital
  • Takeshi Yuasa
    • Department of Transfusion Medicine and Cell TherapyKyoto University Hospital
  • Oliver G. Ottmann
    • Department of HematologyJohann Wolfgang Goethe University
  • Taira Maekawa
    • Department of Transfusion Medicine and Cell TherapyKyoto University Hospital
Case Report

DOI: 10.1007/BF02983531

Cite this article as:
Kimura, S., Kuroda, J., Segawa, H. et al. Int J Hematol (2004) 79: 37. doi:10.1007/BF02983531

Abstract

Bisphosphonates are widely used to treat bone diseases and appear to possess antitumor activity. Moreover, we recently found that a third-generation bisphosphonate, zoledronic acid (ZOL), synergistically interacts with imatinib in vitro and in vivo to induce antileukemic activity, and others have reported that ZOL interacts synergistically with paclitaxel. Thus, the efficacy of other antileukemic agents combined with ZOL should be evaluated experimentally. In this study, we investigated the effects of concurrent and sequential combinations of ZOL with several commonly used antileukemic agents, including imatinib, on the in vitro growth of leukemia cell lines. As a complement to our previous finding that ZOL synergistically augments the effects of imatinib, we report here that ZOL acts additively when administered concurrently with hydroxyurea (HU), cytarabine (Ara-C), or daunorubicin (DNR) in some leukemic cell lines. Furthermore, one day of ZOL pretreatment augmented the sensitivity of imatinib and Ara-C. Therefore, concurrent or sequential administration of ZOL with imatinib, HU, Ara-C, or DNR may increase the efficacy of leukemia treatment.

Key words

Zoledronic acidCytarabineImatinibLeukemiaCombination therapy

Copyright information

© The Japanese Society of Hematology 2004